Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ly2510924 acetate is an potent and selective CXCR4 antagonist. It prevents the binding of SDF-1 to CXCR4 with an IC50 of 0.079 nM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $162 | In Stock | |
5 mg | $323 | In Stock | |
10 mg | $483 | In Stock | |
25 mg | $789 | In Stock | |
50 mg | $1,080 | In Stock | |
100 mg | $1,490 | In Stock | |
1 mL x 10 mM (in DMSO) | $768 | In Stock |
Description | Ly2510924 acetate is an potent and selective CXCR4 antagonist. It prevents the binding of SDF-1 to CXCR4 with an IC50 of 0.079 nM. |
Targets&IC50 | CXCR4:0.079 nM |
In vitro | In human lymphoma U937 cells expressing endogenous CXCR4, LY2510924 acetate inhibited SDF-1-induced cell migration with IC50 value of 0.26 nmol/L and inhibited SDF-1/CXCR4-mediated intracellular signaling. LY2510924 acetate exhibited a concentration-dependent inhibition of SDF-1-stimulated phospho-ERK and phospho-Akt in tumor cells. |
In vivo | LY2510924 acetate showed dose-dependent inhibition of tumor growth in human xenograft models developed with non-Hodgkin lymphoma, renal cell carcinoma, lung, and colon cancer cells that express functional CXCR4. In MDA-MB-231, a breast cancer metastatic model, LY2510924 acetate inhibited tumor metastasis by blocking migration/homing process of tumor cells to the lung and by inhibiting cell proliferation after tumor cell homing. |
Molecular Weight | 1250.49 |
Formula | C64H91N13O13 |
Smiles | O=C(C(NC(C(NC(C(CCCCNC(C)C)N1)=O)CCCNC(N)=O)=O)CC2=CC=C3C=CC=CC3=C2)NCC(N[C@H](CCC(N[C@H](C(N[C@H](C1=O)CC4=CC=C(C=C4)O)=O)CC5=CC=CC=C5)=O)C(N[C@H](C(N)=O)CCCCNC(C)C)=O)=O.CC(O)=O |
Relative Density. | 1.31g/cm3 |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 60 mg/ml (47.98 mM) | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.